N-lauroyl-L-cysteine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-lauroyl-L-cysteine
• 英文别名: N-lauroyl-L-Cys；(2R)-2-(dodecanoylamino)-3-sulfanylpropanoic acid
• 化学式: C₁₅H₂₉NO₃S
• 分子量: 303.466
• InChiKey: SZJKBLZPBALIGH-ZDUSSCGKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  20
• 可旋转键数：
  13
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  67.4
• 氢给体数：
  3
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  N-lauroyl-L-cysteine 在 recombinant Streptomyces mobaraensis aminoacylase 、 水 作用下， 生成 L-半胱氨酸
  参考文献：
  名称：

  Purification, Characterization, Molecular Cloning, and Expression of a New Aminoacylase fromStreptomyces mobaraensisThat Can HydrolyzeN-(Middle/Long)-chain-fatty-acyl-L-amino Acids as Well asN-Short-chain-acyl-L-amino acids

  摘要：

  我们在此报告了一种新的氨酰酶的纯化、特征化、分子克隆和表达，该酶最初从放线菌Mobaraensis（Sm-AA）的上清液中分离出来。纯化的野生型Sm-AA被发现是单体蛋白，分子量为55 kDa。克隆的Sm-AA基因包含一个1,383 bp的开放阅读框（ORF），编码460个氨基酸的多肽。BLAST搜索显示，Sm-AA属于肽酶M20家族，与来自Streptomyces pristinaespiralis的假设蛋白、来自Streptomyces avermitilis的假定肽酶、来自Frankia sp.的肽酶M20、来自流感嗜血杆菌的琥珀酰二氨基庚酸去琥珀酰酶，以及来自猪肾的氨酰酶-1的同源性分别为89%、88%、67%、29%和25%。Sm-AA基因被亚克隆入表达载体pSH19，并在Streptomyces lividans TK24中表达。重组Sm-AA在S. lividans细胞中的表达量约为S. mobaraensis上清液中Sm-AA的42倍。Sm-AA对各种N-乙酰-l-氨基酸和N-(中/长)-链脂肪酰-l-氨基酸表现出高水解活性，特别偏好l-Met、l-Ala、l-Cys等的酰基衍生物，其最佳反应pH和温度约为7.5和50°C（在pH 7.5下）。

  DOI：

  10.1271/bbb.90081
• 作为产物：
  描述：

  月桂酸 、 L-半胱氨酸 在 Streptomyces mobaraensis NBRC 13819 acylase 作用下， 以 甘油 为溶剂， 反应 48.0h， 以32%的产率得到N-lauroyl-L-cysteine
  参考文献：
  名称：

  A Novel Acylase from Streptomyces mobaraensis that Efficiently Catalyzes Hydrolysis/Synthesis of Capsaicins as Well as N-Acyl-l-amino Acids and N-Acyl-peptides

  摘要：

  A novel enzyme that catalyzes efficient hydrolysis of capsaicin (8-methyl-N-vanillyl-6-nonenamide) was isolated from the culture broth of Streptomyces mobaraensis. The enzyme consisted of two dissimilar subunits with molecular masses of 61 and 19 kDa. The enzyme was activated and stabilized in the presence of Co2+. It showed a pH optimum of about 8 and was stable at temperatures of up to 55 degrees C for 1 h at pH 7.8. The specific activity of the enzyme for the hydrolysis of capsaicin was 10(2)-10(4) times higher than those for the enzymes reported to date. In an aqueous/n-hexane biphasic system, capsaicin analogues such as octanoyl, decanoyl, and lauroyl vanillylamides were synthesized from the corresponding fatty acids and vanillylamine at yields of 50% or greater. In addition, the enzyme catalyzed the deacylation of N-lauroyl-L-amino acids and N-lauroyl-L-dipeptides and the efficient synthesis of N alpha-lauroyl-L-lysine, N epsilon-lauroyl-L-lysine, and various N-lauroyl-peptides in aqueous solution in both the absence and the presence of glycerol.

  DOI：

  10.1021/jf052102k

文献信息

• CYSTEINE DERIVATIVES
  申请人：Ajinomoto Co., Inc.

  公开号：EP1120407A1

  公开（公告）日：2001-08-01

  Objects of the present invention are to provide an oxidative stress inhibitor which is capable of suppressing the expression of a cytotoxic protein and the activation of a gene transcriptional regulatory factor taking part such expression of a cytotoxic protein and exhibits good feeling upon use and safety; to provide a method for preventing, retarding, alleviating or treating a skin change due to aging or an undesirable aesthetic skin change, both caused or promoted by an oxidative stress; and to provide a cosmetic composition or dermatologic preparation for external use comprising the oxidative stress inhibitor as an effective ingredient, and for those purposes are employed an oxidative stress inhibiting agent which comprises, as an effective ingredient, at least one selected from cysteine or cystine derivatives and the salts thereof.

  本发明的目的是提供一种氧化应激抑制剂，它能够抑制细胞毒性蛋白的表达和参与细胞毒性蛋白表达的基因转录调控因子的活化，并在使用时具有良好的感觉和安全性；提供一种方法，用于预防、延缓、减轻或治疗由氧化应激引起或促进的皮肤老化变化或皮肤美容方面的不良变化；以及提供一种外用化妆品组合物或皮肤病制剂，其中包含作为有效成分的氧化应激抑制剂，并为此目的采用一种氧化应激抑制剂，其中包含作为有效成分的至少一种选自半胱氨酸或胱氨酸衍生物及其盐类的氧化应激抑制剂。
• PHOTO-CURING MATERIAL MANUFACTURING METHOD, AND PHOTO-CURING MATERIAL AND ARTICLE
  申请人：Asahi Glass Company Limited

  公开号：EP2360195A1

  公开（公告）日：2011-08-24

  To provide a photocurable material which can form a cured product having a high transparency and a high refractive index, a process for producing the material easily, and an article having a high transparency and a high refractive index. The photocurable material is obtained by a production process comprising (i) a step of reacting a polymerizable component (A) comprised of at least one type of a compound (a) having a (meth)acryloyloxy group, and a compound (B) having a mercapto group and a carboxy group to obtain a surface modifier (C) which has the carboxy group derived from the compound (B) at a terminal, (ii) a step of modifying the surface of inorganic fine particles (D) with the surface modifier (C) to obtain surface-modified inorganic fine particles (E), and (iii) a step of obtaining a photocurable material which contains the surface-modified inorganic fine particles (E), a polymerizable component (F) comprised of at least one type of a compound (f) having a (meth)acryloyloxy group, and a photopolymerization initiator (G).

  提供一种可形成具有高透明度和高折射率的固化物的光固化材料、一种易于生产该材料的工艺以及一种具有高透明度和高折射率的制品。 这种光固化材料是通过以下生产工艺获得的： (i) 第一步：使由至少一种具有(甲基)丙烯酰氧基的化合物(a)和具有巯基和羧基的化合物(B)组成的可聚合组分(A)与表面改性剂(C)反应，表面改性剂(C)的末端具有来自化合物(B)的羧基、(ii) 用表面改性剂（C）改性无机微粒（D）的表面，以获得表面改性无机微粒 （E），以及 (iii) 获得光固化材料的步骤，该材料包含表面改性无机微粒（E）、由至少一种具有 （甲基）丙烯酰氧基的化合物（f）和光聚合引发剂（G）组成的可聚合组分（F）。
• Pharmaceutical formulations for the oral delivery of peptide or protein drugs
  申请人：Cyprumed GmbH

  公开号：EP3006045A1

  公开（公告）日：2016-04-13

  The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide or protein drugs with advantageously high bioavailability, safety and cost-effectiveness. In particular, the invention provides a peptide or protein drug having a molecular weight of equal to or less than about 50 kDa for use as a medicament, wherein said peptide or protein drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex, and with a pharmaceutically acceptable reducing agent. The invention also provides a pharmaceutical composition comprising: a peptide or protein drug having a molecular weight of equal to or less than about 50 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex; and a pharmaceutically acceptable reducing agent.

  本发明涉及肽或蛋白质药物口服给药的改进药物制剂、用途和方法，具有生物利用度高、安全性好和成本效益高等优点。特别是，本发明提供了一种分子量等于或小于约 50 kDa 的多肽或蛋白质药物，可用作药物，其中所述多肽或蛋白质药物将与药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物以及药学上可接受的还原剂一起口服给药。本发明还提供了一种药物组合物，其中包括：分子量等于或小于约 50 kDa 的多肽或蛋白药物；药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物；以及药学上可接受的还原剂。
• Fast-acting plant-based medicinal compounds and nutritional supplements
  申请人：RECEPTOR HOLDINGS, INC.

  公开号：US10588974B2

  公开（公告）日：2020-03-17

  Plant-based medicinal compounds or nutritional supplements in various carrier combinations are described. The carriers can include N-acylated fatty amino acids, penetration enhancers, and/or various other beneficial carriers. The plant-based composition/carrier combinations can create administration benefits.

  本文介绍了各种载体组合中的植物药用化合物或营养补充剂。载体可包括 N-酰化脂肪氨基酸、渗透促进剂和/或其他各种有益载体。植物性组合物/载体组合可带来用药益处。
• Pharmaceutical formulations for the oral delivery of peptide drugs
  申请人：Cyprumed GmbH

  公开号：US10905744B2

  公开（公告）日：2021-02-02

  The present invention relates to improved pharmaceutical formulations, uses and methods for the oral delivery of peptide drugs with advantageously high bioavailability, safety and costeffectiveness. In particular, the invention provides a peptide drug having a molecular weight of equal to or less than 5 kDa for use as a medicament, wherein said peptide drug is to be administered orally in combination with a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex, and with a pharmaceutically acceptable complexing agent. The invention also provides a pharmaceutical composition comprising: a peptide drug having a molecular weight of equal to or less than 5 kDa; a pharmaceutically acceptable copper salt/complex and/or a pharmaceutically acceptable zinc salt/complex and/or a pharmaceutically acceptable iron salt/complex; and a pharmaceutically acceptable complexing agent.

  本发明涉及肽类药物口服给药的改进药物制剂、用途和方法，具有生物利用度高、安全和成本效益高等优点。特别是，本发明提供了一种分子量等于或小于 5 kDa 的多肽药物，可用作药物，其中所述多肽药物将与药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物和/或药学上可接受的铁盐/络合物以及药学上可接受的络合剂一起口服给药。本发明还提供了一种药物组合物，其中包括：分子量等于或小于 5 kDa 的多肽药物；药学上可接受的铜盐/络合物和/或药学上可接受的锌盐/络合物和/或药学上可接受的铁盐/络合物；以及药学上可接受的络合剂。